Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
6 January 2025 |
Main ID: |
NCT05506254 |
Date of registration:
|
16/08/2022 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy
|
Scientific title:
|
A Long-term Follow-up Study of Patients in LogicBio Clinical Trials for Methylmalonic Acidemia Characterized by MMUT Mutations Who Received hLB-001 |
Date of first enrolment:
|
July 20, 2022 |
Target sample size:
|
4 |
Recruitment status: |
Active, not recruiting |
URL:
|
https://clinicaltrials.gov/ct2/show/NCT05506254 |
Study type:
|
Observational |
Study design:
|
|
Phase:
|
|
|
Countries of recruitment
|
United States
| | | | | | | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Participant has previously participated in a LogicBio clinical trial and received
hLB-001.
Exclusion Criteria:
- None
Age minimum:
N/A
Age maximum:
N/A
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Methylmalonic Acidemia
|
Intervention(s)
|
Drug: hLB-001
|
Primary Outcome(s)
|
Incidence of treatment emergent adverse events
[Time Frame: 15 years]
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|